VHL and Hypoxia Signaling: Beyond HIF in Cancer
AbstractVon Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer. View Full-Text
Share & Cite This Article
Zhang, J.; Zhang, Q. VHL and Hypoxia Signaling: Beyond HIF in Cancer. Biomedicines 2018, 6, 35.
Zhang J, Zhang Q. VHL and Hypoxia Signaling: Beyond HIF in Cancer. Biomedicines. 2018; 6(1):35.Chicago/Turabian Style
Zhang, Jing; Zhang, Qing. 2018. "VHL and Hypoxia Signaling: Beyond HIF in Cancer." Biomedicines 6, no. 1: 35.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.